European Commission Expands Role of Gileads Trodelvy in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) for the treatment of adult patients with unresectable, locally advanced or metastatic...